Deuterated DMT Compositions for Extended Psychedelic Duration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing psychedelic drugs like N,N-dimethyltryptamine (DMT) have a short duration of action, limiting therapeutic efficacy due to their rapid onset and short half-life, making effective therapy challenging, and prolonged administration protocols carry risks for poor metabolizers.
Innovation Solution
Compositions comprising mixtures of N,N-dimethyltryptamine and deuterated analogues, particularly with deuterium at the alpha and beta positions, to control pharmacokinetic profiles, allowing a single dose to maintain therapeutic effects for a desired duration without infusion protocols or combination therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If N,N-dimethyltryptamine is administered to achieve therapeutic effects, then psychiatric disorders can be treated, but the duration of action is too short (under 20 minutes) to maintain effective therapy
Solution Approach 1:
The patent applies parameter changes by substituting hydrogen atoms with deuterium atoms at specific positions (alpha and/or beta positions) on the DMT molecule. This isotopic substitution modifies the pharmacokinetic parameters of the compound, specifically extending its half-life and duration of action while maintaining its therapeutic psychedelic effects. The deuterated analogues demonstrate prolonged presence in the body compared to non-deuterated DMT, thereby resolving the contradiction between short duration and therapeutic reliability.
2Duration of action of moving object
If infusion protocols are used to extend the duration of DMT effects, then therapeutic duration is improved, but toxic buildup occurs in poor metabolizers
Solution Approach 1:
The patent modifies the metabolic parameters of DMT through deuterium substitution, which alters the rate of metabolism and elimination. The deuterated analogues exhibit slower metabolic clearance compared to non-deuterated DMT, naturally extending their duration of action without requiring continuous infusion. This approach avoids the toxic buildup associated with prolonged infusion protocols in poor metabolizers, as the extended duration is achieved through modified pharmacokinetics rather than sustained high-dose administration.
3Duration of action of moving object
If combination therapy with monoamine oxidase inhibitors is used to prolong DMT effects, then duration is extended, but clinical complexity increases
Solution Approach 1:
The patent employs parameter changes through deuterium isotopic substitution to inherently prolong the duration of DMT effects at the molecular level. This modification is built into the drug substance itself, eliminating the need for combination therapy with monoamine oxidase inhibitors or other adjunctive medications. The result is a simplified clinical protocol where a single deuterated DMT compound provides extended therapeutic duration without requiring complex combination regimens.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Provides a clinically applicable solution that extends the duration of psychedelic effects for therapeutic use, reducing clinical complexity and increasing flexibility in DMT-assisted psychotherapy.
Implementation Method 1
a,a,β,β-Tetradeutero-N,N-dimethyltryptamine is known to exhibit a kinetic isotope effect which bestows a significant difference on its in vivo pharmacokinetic profile as compared with N,N-dimethyltryptamine
Data Source
Figure 1A~1B
Figure 2A~3B
AI summary
The present invention relates to compositions comprising two or more compounds selected from (a) an a,a-dideutero-N,N-dimethyltryptamine compound, and (b) an a-protio, a-deutero-N,N-dimethyltryptamine compound, and pharmaceutically acceptable salts of these compounds; wherein the composition comprises 50% or more by weight of the a,a-dideutero-N,N-dimethyltryptamine compound, or a pharmaceutically acceptable salt thereof, or 50% or more by weight of the a-protio, a-deutero-N,N-dimethyltryptamine compound, or a pharmaceutically acceptable salt thereof. Said compositions for use in treating psychiatric or psychocognitive disorders, such as major depressive disorder, are also provided.